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Abstract
Overexpression or mutation of a-Synuclein is associated with protein aggregation and interferes with a number of cellular
processes, including mitochondrial integrity and function. We used a whole-genome screen in the fruit fly Drosophila
melanogaster to search for novel genetic modifiers of human [A53T]a-Synuclein–induced neurotoxicity. Decreased
expression of the mitochondrial chaperone protein tumor necrosis factor receptor associated protein-1 (TRAP1) was found
to enhance age-dependent loss of fly head dopamine (DA) and DA neuron number resulting from [A53T]a-Synuclein
expression. In addition, decreased TRAP1 expression in [A53T]a-Synuclein–expressing flies resulted in enhanced loss of
climbing ability and sensitivity to oxidative stress. Overexpression of human TRAP1 was able to rescue these phenotypes.
Similarly, human TRAP1 overexpression in rat primary cortical neurons rescued [A53T]a-Synuclein–induced sensitivity to
rotenone treatment. In human (non)neuronal cell lines, small interfering RNA directed against TRAP1 enhanced [A53T]a-
Synuclein–induced sensitivity to oxidative stress treatment. [A53T]a-Synuclein directly interfered with mitochondrial
function, as its expression reduced Complex I activity in HEK293 cells. These effects were blocked by TRAP1 overexpression.
Moreover, TRAP1 was able to prevent alteration in mitochondrial morphology caused by [A53T]a-Synuclein overexpression
in human SH-SY5Y cells. These results indicate that [A53T]a-Synuclein toxicity is intimately connected to mitochondrial
dysfunction and that toxicity reduction in fly and rat primary neurons and human cell lines can be achieved using
overexpression of the mitochondrial chaperone TRAP1. Interestingly, TRAP1 has previously been shown to be
phosphorylated by the serine/threonine kinase PINK1, thus providing a potential link of PINK1 via TRAP1 to a-Synuclein.
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Introduction
Parkinson’s disease (PD) is the second most prevalent neurode-
generative disease behind Alzheimer’s disease (AD), with an
incidence rate of approximately 110–300 per 100,000 persons
above the age of 50 [1]. The movement disorder is characterized
by the selective death of dopaminergic neurons in the substantia
nigra pars compacta (SNc) [2]. Death of SNc neurons results in a
reduction of dopamine (DA) levels within their key efferent target,
the striatum [3]. Mitochondrial Complex I activity deficit and
evidence of enhanced oxidative stress within affected brain regions
are also observed in PD [4–6]. Age and pesticide/herbicide
exposure are the most important disease risk factors [7–9].
Importantly, there is no clinical therapy available that has been
shown to slow or reverse PD.
While the majority of PD is diagnosed as idiopathic, 5–10% of
cases are attributable to familial forms of PD [10]. Although
genetic PD represents only a small percentage of patients,
mutations in these genes point to underlying biochemical
pathways that could also be relevant to sporadic PD patients.
Three missense mutations in the small pre-synaptic protein a-
Synuclein (SNCA/PARK1/4; GenBank ID 6622) have been
shown to result in autosomal-dominant PD. A critical effect of
protein dose on pathology is implicated by disease-causing gene
duplication and triplication [11–14]. a-Synuclein is also a major
protein component of the Lewy Bodies (LB), the key histologic
feature of dopaminergic and non-dopaminergic neurons found in
PD patients [15]. Thus, a-Synuclein is strongly suggested to be a
causal factor in PD pathogenesis.
Human a-Synuclein mutation or overexpression results in
cytotoxicity, with [A53T]a-Synuclein being the most toxic variant
known. Direct cell loss can be induced in both in vitro and in vivo
models of yeast, C. elegans, Drosophila, rat, mouse, and non-human
primate [16–23]. The formation of a-Synuclein oligomers from
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results in dysfunction of multiple cell systems such as the ubiquitin
proteasome system, the endoplasmic reticulum and lysosomes [24–
31]. Recent data also suggests that a-Synuclein plays a role in
modulating both mitochondrial function and damage. a-Synu-
clein-overexpressing cells exhibit multiple markers of mitochon-
drial dysfunction, including increased protein oxidation, increased
ROS production, loss of mitochondrial membrane potential and
reduced Complex I activity [32–38]. Several groups have
demonstrated that a-Synuclein’s entry in mitochondria is
mediated via an N-terminal mitochondrial targeting sequence,
with localization at the inner membrane [37,38]. Moreover, PD
patient brain histology shows a-Synuclein accumulation within
mitochondria of the SNc and striatum, a feature absent in control
brains [38]. Mitochondrial dysfunction associated with adenosine
triphosphate (ATP) depletion and electron transport chain (ETC)
defects reduces the cell’s ability to handle oxidative protein
damage and cellular tasks, suggesting a possible reason for cell
death.
In PD patient brains, early DA reduction indicates the
withdrawal of SNc striatal projections, finally resulting in DA
neuron loss and PD-related symptoms of rigidity and akinesia. In
flies, expression of [A53T]a-Synuclein is accompanied by an age-
dependent loss of DA and DA neurons, respectively. Thus, fly
head DA levels provide an indirect readout for [A53T]a-
Synuclein-induced toxicity. To further investigate the mechanism
and identify novel modifiers of a-Synuclein toxicity, we performed
a genome-wide genetic screen in Drosophila. In this screen, we
identified, among other gene products, the mitochondrial
chaperone protein TRAP1 (GenBank ID 10131) as a novel
modifier of [A53T]a-Synuclein-induced DA loss. TRAP1 has
previously been shown to function downstream of the PD-related
serine/threonine kinase PINK1 (GenBank ID 65018). PINK1-
induced phosphorylation of TRAP1 seems to be necessary for the
protein’s protective effects against oxidative stress [39]. In our
report we further characterize the functional consequences of
TRAP1 reduction or overexpression in Drosophila, in primary
neurons and dopaminergic cell lines and the effects on
mitochondrial morphology and function.
Results
Expression of Human [A53T]a-Synuclein in Fly Heads and
Genetic Screening for Modification of [A53T]a-Synuclein
Toxicity
Expression of a-Synuclein in Drosophila is established as a useful
model of PD [21]. As the fly lacks an a-Synuclein homolog, this
model relies on ectopic expression of human a-Synuclein using the
UAS/GAL4 system [40]. We have previously analyzed DA neuron
number in aged flies, expressing different mutant variants of a-
Synuclein. Compared to controls, wild type a-Synuclein did not
cause a decline in DA neuron number. Moreover, locomotion was
not impaired in aged wild type a-Synuclein-expressing flies [41].
Based on these results, we chose [A53T]a-Synuclein for our
screening. With single copy expression of a UAS:[A53T]a-Synuclein
transgene (A53T) in aminergic neurons (dopa decarboxylase-GAL4
driver, ddc-GAL4) (Figure 1A), no difference to overall fly fitness, as
assessed by longevity, was observed (Figure 1B). In contrast,
expression of two transgene copies, resulting in higher expression
levels (Figure 1A), caused earlier lethality compared to controls
(Figure 1B). However, when we measured DA levels of flies
expressing one copy of [A53T]a-Synuclein under control of ddc-
GAL4 (ddc.A53T), we noticed a significant decrease in DA levels
with aging (Figure 1C). Thus, measuring DA levels using high
performance liquid chromatography represents a sensitive system
to address DA levels in fly heads. After carefully addressing
sensitivity, specificity and reproducibility of our readout marker
(Figure 1D, Figure S1), we decided to perform a genome-wide
screen to identify modifiers of [A53T]a-Synuclein-induced DA
loss in vivo. Thus, flies with expression of [A53T]a-Synuclein in
aminergic neurons were crossbred to fly lines carrying chromo-
somal deletions (deficiencies), utilizing the ‘‘Bloomington Defi-
ciency Kit’’. Progeny were screened for changes in DA loss over
time (a summary of the screen results is given in Text S1 and
Tables S1, S2, S3, S4). Although detailed single gene analysis is
still ongoing, we identified a large number of genes coding for
proteins involved in mitochondrial function within the candidate
deficiencies. Therefore, we additionally cross-referenced our data
with results from a genome-wide RNAi-screen, set to identify
modulators of mitochondrial function [42]. Common genes were
screened for alteration of [A53T]a-Synuclein-toxicity with respect
to viability and DA loss.
TRAP1 Modification of [A53T]a-Synuclein Toxicity in the
Fly
Among the deficiencies screened, Df(2R)nap9 caused the greatest
enhancement of [A53T]a-Synuclein-induced DA loss of all non-
lethal interacting deficiencies. Of the 153 genes deleted by
Df(2R)nap9, we found TRAP1 reduction to enhance [A53T]a-
Synuclein-induced DA loss. The loss-of-function allele
TRAP1[KG06242] (hereafter referred to as TRAP1[KG], Figure
S2) caused a reduction of fly head DA levels similar to those of
Df(2R)nap9 (data not shown). However, TRAP1[KG] did not alter
DA levels (Figure 1D). Thus, flies with reduced TRAP1 in
combination with the ddc-GAL4 driver (TRAP1[KG]/+; ddc/+)
served as controls in later analysis. TRAP1 is a mitochondrial
chaperone, recently reported as a downstream phosphorylation
target of the PD protein PINK1 in rat and human cell lines [39].
As both fly and human TRAP1 share high sequence homology, we
generated a UAS-transgenic fly to express human TRAP1
Author Summary
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder, pathologically characterized by loss of
dopaminergic neurons in the substantia nigra pars
compacta brain region. Mutations in a-Synuclein or gene
duplication or triplication result in autosomal-dominant
inherited PD. Indeed, aggregated and insoluble a-Synu-
clein is found in Lewy bodies, a pathological hallmark
common to both sporadic and hereditary forms of PD. In
order to better define a-Synuclein’s pathogenic mecha-
nism, we first used a fly genetic screen to search for novel
genetic modifiers of mutant human [A53T]a-Synuclein
neurotoxicity. We identified the mitochondrial chaperone
protein TRAP1 as a novel modifier of the toxicity induced
by [A53T]a-Synuclein. [A53T]a-Synuclein–induced toxicity
was enhanced when TRAP1 expression was decreased,
while overexpression of human TRAP1 (hTRAP1) provided
a rescue. Cell culture experiments further demonstrated
that [A53T]a-Synuclein directly interferes with a number of
mitochondrial functions, including Complex I ATP produc-
tion, mitochondrial fragmentation, and sensitivity to
oxidative stress. These effects could be blocked by TRAP1
overexpression. As mitochondrial dysfunction has previ-
ously been linked to mutations in several other genes
associated with genetic PD, these data provide further
evidence of a common mitochondrial-centric mechanism
of PD pathogenesis.
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was able to provide a rescue effect against [A53T]a-Synuclein-
induced DA loss (Figure 2A). The effects of TRAP1 on DA levels
were also reflected by its effect on tyrosine hydroxylase (TH)-
positive neurons. ddc.A53T expressing flies showed increased loss
of TH-positive neurons if TRAP1 levels were reduced (Figure 2B).
In contrast, hTRAP1 overexpression was able to restore [A53T]a-
Synuclein-induced loss of TH-positive neurons to control levels.
Interestingly, ddc-driven overexpression of hTRAP1 did not
increase longevity of ddc.A53T heterozygous flies (not shown).
In PD patients, a reduction in brain DA content is later followed
by neuronal decline. The same seems to hold true for flies.
Although no reduction in longevity of ddc.A53T/+ flies is
observed, these flies display a significant reduction in DA content.
A more pronounced DA reduction (ddc.A53T/ddc.A53T) results
in neuronal decline, eventually leading to early death, reflected by
a significantly shortened lifespan (Figure 1B). This might explain
why TRAP1 will still provide 100% protection against loss of
neurons (Figure 2B), even if DA levels have already started to
decline (Figure 2A).
PD is clinically defined as a movement disorder. Thus, key to an
animal disease model recapitulating this phenotype is loss of
locomotor ability. Locomotion in flies is measurable using the
negative geotaxis assay. In agreement with previous reports,
ddc.A53T flies showed an age-related deficit in climbing ability
[21,43]. Notably, ddc-driven hTRAP1 expression was able to
significantly rescue the locomotion deficit in ddc.A53T flies
(Figure 2C). Therefore, taken together, these data indicate that the
rescue of head DA content is sufficient to restore motor ability.
Our data suggest that TRAP1 protects from toxic effects
induced by [A53T]a-Synuclein. However, TRAP1 might also
provide protection to any toxic insult. To address this possibility,
we examined if TRAP1 provides protection against toxicity
induced by the expression of other well-known toxic proteins/
peptides.
Eye-specific expression (GMR-GAL4) of either human Tau or
SCA3-derived polyglutamine stretches (PolyQ) in the fly eye result
in a rough eye phenotype (REP). These REPs are sensitive to
genetic modifiers and have successfully been used for screening
[44,45]. Interestingly, overexpression of TRAP1 did not show a
rescue of the PolyQ-induced REP. Moreover, silencing of TRAP1
by RNAi did not enhance the REP (Figure 2D). Similar results
were obtained with Tau-expressing flies (not shown). A general
protective role of TRAP1 in any toxic trigger is therefore unlikely
but appears to be specific for a-Synuclein toxicity.
Modification of [A53T]a-Synuclein Toxicity by TRAP1 in
Rat Primary Cortical Neuron Culture
In flies, overexpression of hTRAP1 was able to reduce
[A53T]a-Synuclein-induced loss of DA in fly heads and loss of
DA neurons, respectively. Thus, to additionally confirm that
overexpression of hTRAP1 is able to rescue [A53T]a-Synuclein-
induced sensitivity in vertebrate neurons, we used terminally-
differentiated rat primary neuron cultures. Lentiviral infection
specificity and efficacy in these cells was first verified (Figure 3A,
3B). As the neurons did not display robust toxicity upon [A53T]a-
Synuclein expression alone, cells were exposed to low doses of the
mitochondrial Complex I inhibitor rotenone. Compared to GFP-
virus infected cells (control), co-expression of [A53T]a-Synuclein
significantly enhanced cell loss (Figure 3C). In agreement with fly
data, coincident overexpression of TRAP1 restored survival to
control values. Interestingly, expression of TRAP1 alone enhanced
survival beyond that of control cells, indicative of a protective
Figure 1. [A53T]a-Synuclein expression in fly heads results in
age-dependent loss of DA. (A) Western blot showing abundance of
human [A53T]a-Synuclein after aminergic neuron (ddc-GAL4)-specific
expression in lysates of fly heads. While flies without [A53T]a-Synuclein
transgene do not show any detectable signal for [A53T]a-Synuclein in
Western blot, an increase of [A53T]a-Synuclein protein levels was
observed by increasing the copy number of transgenes. Syntaxin served
as a loading control and molecular weight markers are indicated. (B)
Whereas ddc.A53T/+ flies displayed no significant difference in
longevity as compared to ddc/+ flies, flies homozygous for ddc.A53T
showed a significant decrease (p,0.001, Log rank test). (C) Compared
to controls (ddc/+), ddc.A53T/+ flies showed a significant age-
dependent loss of DA at 3 and 4 weeks post eclosion (*p,0.05 vs.
control). (D) Only ddc.A53T flies showed a significant decrease
(***p,0.001) in DA concentration in fly heads at 4 weeks. Comparisons
of multiple controls were not significant (4 week values as per cent of 1
week values; ANOVA followed by Newman-Keuls Multiple Comparison
Test).
doi:10.1371/journal.pgen.1002488.g001
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PLoS Genetics | www.plosgenetics.org 3 February 2012 | Volume 8 | Issue 2 | e1002488Figure 2. TRAP1 overexpression mitigates detrimental effects induced by neuronal [A53T]a-Synuclein expression. (A) Overexpression
of [A53T]a-Synuclein under control of ddc-GAL4 resulted in reduction of DA in fly heads at 4 weeks, which was potentiated by TRAP1 deficiency
(TRAP1[KG]/+;ddc.A53T/+), but mitigated by TRAP1 overexpression (ddc.A53T/hTRAP1). (B) ddc.A53T flies display a reduction of TH-positive
neurons, which was potentiated by TRAP1 deficiency, but rescued to control levels by TRAP1 overexpression. (C) In negative geotaxis assays
ddc.A53T flies displayed a time-dependent decline in locomotion. Reduction of TRAP1 enhanced the inability to climb (although not significant),
while overexpression of hTRAP1 provided a significant rescue effect (comparison of ddc.A53T/+ vs ddc.A53T/hTRAP1 at 4 weeks: p,0.05). Statistics
in (A, B): ANOVA followed by Newman-Keuls Multiple Comparison Test; (C): 2-way ANOVA followed by Bonferroni post-hoc tests. Displayed are
biologically relevant comparisons. *p,0.05; **p,0.01; ***p,0.001; ns=not significant. (D) Alterations in TRAP1 levels did not influence PolyQ-
induced rough eye phenotypes. Light micrographs of external eye structures show that PolyQ-induced REP was suppressed by parallel expression of
HSP70. In contrast, neither overexpression of hTRAP1 or silencing of endogenous TRAP1 by RNAi had an obvious impact on external eye structure.
Expression of mitochondrial localized GFP (mito-GFP) served as control.
doi:10.1371/journal.pgen.1002488.g002
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Synuclein-induced toxicity.
Modification of [A53T]a-Synuclein Toxicity by TRAP1 in
Human HEK293 Cell Culture
To study the functional role of TRAP1, we used both TRAP1
overexpression and specific knockdown by small interfering RNA
(siRNA) in human embryonic kidney cells-293 (HEK293) cells.
Two different siRNAs directed against TRAP1 were first
compared for efficacy. Both were able to reduce endogenous
TRAP1 expression in HEK293 cells (Figure S3). The most
efficient siRNA was used for all further investigations.
To confirm whether treatment of HEK293 cells mimicked the in
vivo fly and in vitro rat neuron data concerning TRAP1 and stress
sensitivity, HEK293 cells were treated overnight with a low dose of
either hydrogen peroxide (Figure 4A) or the Complex I inhibitor
rotenone (Figure 4B). [A53T]a-Synuclein expression enhanced
cell sensitivity to both stressors. Reduction in TRAP1 expression
further reduced survival in the presence of [A53T]a-Synuclein.
For both, rotenone and hydrogen peroxide treatment, overex-
pression of TRAP1 in the context of [A53T]a-Synuclein
expression attenuated the decrease in cell survival. The magnitude
of the rescue effect was greatest when cells were exposed to
rotenone (Figure 4A, 4B). In cells without [A53T]a-Synuclein
expression, reduction of TRAP1 also caused stress sensitization.
These data corroborate the reported function of TRAP1 as a
protective mitochondrial chaperone [46–48].
Previous reports have indicated that [A53T]a-Synuclein may
interfere with mitochondrial respiration, in particular with
Complex I function [34]. Given the noted rescue effect of TRAP1
on rotenone-treated cells with or without [A53T]a-Synuclein
expression, we hypothesized that the TRAP1 effect on [A53T]a-
Synuclein may in part be related to altered ETC function. Thus,
ATP production via Complex I was assayed in cells without
oxidative stress, to evaluate the general effects of [A53T]a-
Synuclein on ETC in combination with altered TRAP1 levels.
Expression of [A53T]a-Synuclein reduced Complex I activity in
HEK293 cells (Figure 4C). TRAP1-silencing enhanced this
reduction, while TRAP1 overexpression rescued the [A53T]a-
Synuclein-induced defect. In light of the defects observed in
[A53T]a-Synuclein-induced Complex I ATP production
(Figure 4C), total ATP levels in the cell were also investigated.
Only cells expressing [A53T]a-Synuclein in combination with
siTRAP1 showed a reduction of total ATP levels (Figure 4D).
Although [A53T]a-Synuclein alone significantly reduced Complex
I activity, overall ATP levels were unchanged.
Loss of mitochondrial membrane potential predisposes cells to
apoptosis. [A53T]a-Synuclein has been suggested to adopt an
alpha-helical conformation that could perforate membranes. At
the same time, TRAP1 protection against apoptosis has been
suggested to act via inhibition of opening mitochondrial
permeability transition pore (PTP) [49]. The mitochondrial
membrane potential is thought to indirectly reflect the state of
the PTP. Cells were thus assessed for mitochondrial membrane
potential using the mitochondrial membrane dye, JC-1. Only cells
expressing [A53T]a-Synuclein in combination with siTRAP1
showed a loss of mitochondrial membrane potential (Figure 4E).
Finally, to exclude the possibility that altered Complex I ATP
production might be due to varying quantites of mitochondria
Figure 3. TRAP1 overexpression protects rat cortical neurons from [A53T]a-Synuclein-induced sensitivity to rotenone. (A) Western
blot analysis of cells infected with lentivirus promoting either GFP, TRAP1 or [A53T]a-Synuclein expression. For visualization, the blot was probed with
either TRAP1- or a-Synuclein-specific antibodies, respectively. ß-Actin was used for normalization. (B) Rat cortical neurons infected with lentivirus
promoting GFP expression were stained for neuronal marker NeuN (red) and DNA (Hoechst, blue). A high percentage of cells showed co-localization
between GFP and the neuronal marker NeuN, indicative for high infection efficacy. Scale bar indicates 43 mm. (C) Quantification of cell survival after
16 h of rotenone treatment of cells infected with viruses mediating expression of indicated protein. Significant differences compared to control (GFP)
are indicated. All other comparisons revealed highly significant differences (p,0.001) in statistical analysis (ANOVA followed by Newman-Keuls
Multiple Comparison Test). **p,0.01; ***p,0.001; ns=not significant.
doi:10.1371/journal.pgen.1002488.g003
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samples were probed for two mitochondrial proteins, VDAC1 and
COX4. No major differences were observed for expression of
VDAC1 and COX4 (Figure S4A). This suggests the detected
decrease in Complex I ATP production resulted from a functional
ETC deficit. JC-1 is an excellent dye to measure mitochondrial
membrane potential and because of the color switch following
depolarization, it makes it easy to normalize to cell density.
However, JC-1 has been superseded by other dyes, like TMRM,
with respect to the potential artifact of local concentration
changes. With regard to this potential problem, we repeated
mitochondrial membrane potential measurements using TMRM.
In addition, we wanted to exclude potential off-target effects by
siRNA treatment. Therefore, we generated HEK293 cells with
stable expression of shTRAP1 constructs resulting in a roughly
90% loss of TRAP1 protein levels (Figure S5A). In stable TRAP1-
silenced cells, a significant reduction in membrane potential was
observed after [A53T]a-Synuclein expression. This effect was
absent in cells expressing scrambled shRNA, again indicating that
TRAP1-silencing in combination with [A53T]a-Synuclein expres-
sion causes opening of mitochondrial PTP (Figure S5B).
Effect of TRAP1 Mutation on [A53T]a-Synuclein–Induced
Toxicity
The human TRAP1 ATPase domain shares high homology
with both other HSP90 proteins and TRAP1 orthologs found in
other species (Figure S6). Recently, the ATPase domain of yeast
HSP90 has been shown to be required for its HSP90 function. The
mutation of a specific amino acid within the ATPase domain was
sufficient to inhibit ATP binding [50]. This amino acid is highly
conserved in both HSP90 and TRAP1 proteins (Figure S6). We
Figure 4. Alterations in TRAP1 levels influence [A53T]a-Synuclein-induced sensitivity to oxidative stress and mitochondrial effects
in HEK293 cells. HEK293 cells were transfected with plasmids promoting [A53T]a-Synuclein or TRAP1 expression. Empty vector transfection served
as control. In addition, RNAi-mediated silencing of endogenous TRAP1 was induced (siTRAP1). Cells transfected with indicated plasmid combinations
were treated with (A) hydrogen peroxide (100 mm) or (B) rotenone (200 mM) to induce oxidative stress. Cell numbers were analyzed to monitor
survival. (C–E) HEK293 without oxidative stress treatment overexpressing the indicated proteins, or with RNAi-mediated silencing of TRAP1 were
analyzed for (C) ATP production via Complex I, (D) total ATP content, and (E) mitochondrial membrane potential. Statistical analysis of displayed bar
graphs was performed using ANOVA followed by Newman-Keuls Multiple Comparison Test. (A, B) Biologically relevant comparisons are indicated in
bar graphs. (C) Differences compared to control are indicated. (A, B, C) A detailed summary of all comparisons is summarized in Figure S8. (D, E) Only
cells with [A53T]a-Synuclein expression and TRAP1 reduction displayed significant differences in statistical analysis as indicated in graph. All other
comparisons were not significant. *p,0.05; **p,0.01; ***p,0.001; ns=not significant.
doi:10.1371/journal.pgen.1002488.g004
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asparagine (TRAP1[D158N]), creating a putative non-functional
ATPase domain. Introducing the D158N mutation did not
interfere with TRAP1 protein turnover, as expression in
HEK293 cells resulted in similar abundance of TRAP1[D158N]
and TRAP1[WT] proteins (Figure 5A).
Next, we asked if TRAP1[D158N] is as effective as
TRAP1[WT] in protecting [A53T]a-Synuclein-expressing cells
from oxidative stress. Cells overexpressing [A53T]a-Synuclein
treated overnight with rotenone displayed a robust reduction in
cell survival, which was rescued by TRAP1[WT] overexpression
(Figure 4B). In contrast, overexpression of TRAP1[D158N] was
less effective (Figure 5B). Similar results were observed when we
tested ATP production by Complex I. In the context of [A53T]a-
Synuclein expression without oxidative stress, TRAP1[WT]
rescued [A53T]a-Synuclein-induced decrease in Complex I ATP
production (Figure 5C), while TRAP1[D158N] showed signifi-
cantly lower degree of rescue ability. Finally, cell lysates were again
analyzed for abundance of the mitochondrial proteins VDAC1
and COX4. No changes in VDAC1 or COX4 protein levels were
observed in cell lysates expressing either TRAP1[WT] or mutant
TRAP1[D158N] (Figure S4B). These data thus indicate that
mutant TRAP1 expression does not alter the overall mitochon-
drial content, arguing in favor of a functional ETC Complex
deficit, rather than a deficit due to diminished numbers of
mitochondrial/ETC components in the cell.
Recent data show that a-Synuclein impairs mitochondrial
fusion, leading to fragmented mitochondria. Interestingly, the a-
Synuclein-induced mitochondrial fragmentation can be attenuated
by co-expression of PINK1, Parkin and DJ-1, but not by PD-
linked mutant variants of these proteins [51]. Therefore, we sought
to determine if TRAP1 is also able of attenuating a-Synuclein-
induced mitochondrial fragmentation in SH-SY5Y cells. The
[A53T]a-Synuclein-induced punctate mitochondrial staining was
reversed to a tubular mitochondrial network by TRAP1[WT] co-
expression. In contrast, co-expression of TRAP1[D158N] showed
no effect (Figure 6A, 6B). The expression of both TRAP1 variants
alone had no impact on mitochondrial integrity. Verification of
protein expression levels revealed robust a-Synuclein and TRAP1
expression after transfection with respective plasmids (Figure 6C).
Thus, the impaired rescue ability of TRAP1[D158N] in
comparison to TRAP1[WT] cannot be explained by the lower
abundance of TRAP1[D158N] protein. It is rather the conse-
quence of an altered function of the inherent ATPase function of
TRAP1[D158N]. In addition, we asked if reduced TRAP1 levels
might enhance mitochondrial fragmentation induced by [A53T]a-
Synuclein expression. We noticed that TRAP1-silencing increased
the number of cells with fragmented mitochondria. Combining
TRAP1-silencing with [A53T]a-Synuclein expression enhanced
fragmentation of mitochondria even further (Figure 7A, 7B).
Effective TRAP1-silencing and [A53T]a-Synuclein expression was
confirmed by Western blot analysis (Figure 7C).
Localization of [A53T]a-Synuclein to Mitochondria and
Protein–Protein Interaction with TRAP1 in HEK293 Cell
Culture
TRAP1 is defined as a mitochondrial molecular chaperone and
has been shown to be protective against oxidative stress-induced
cell death via multiple postulated mechanisms including cyto-
chrome c release inhibition, interference with caspase-3 activation
and attenuation of ROS production [39,46,48,52–54]. We thus
hypothesized that TRAP1 might directly antagonize a-Synuclein
mitochondrial-related toxicity. Confirming that TRAP1 is indeed
found in the mitochondria, co-localization studies in HEK293 cells
revealed a strong overlap between TRAP1 staining with
‘‘Mitotracker Orange’’-labeled mitochondria (Figure S7A). There-
fore, it was interesting to see if a-Synuclein might also localize with
mitochondria, as previously reported [33,37,38]. To determine
this, we performed cell fractionation experiments to separate
cytoplasmic and mitochondrial enriched fractions. Using Western
Figure 5. Effect of TRAP1 mutation on modification of [A53T]a-Synuclein toxicity. (A) Western blot analysis of HEK293 lysates transfected
with indicated constructs showed similar expression levels of TRAP1[WT] and TRAP1[D158N] and a reduction of endogenous TRAP1 by siTRAP1. Blot
was probed with TRAP1-specific antibody. ß-Actin served as loading control. (B, C) Effect of TRAP1[WT] and TRAP1[D158N] on [A53T]a-Synuclein-
induced effects in HEK293 cells. (B) Effect of TRAP1[D158N] on [A53T]a-Synuclein-induced toxicity. Cell survival after rotenone (200 mM) treatment
was monitored. Compared to TRAP1[WT], cells expressing TRAP1[D158N] displayed a significant reduction in survival (t-test, **p,0.01). (C)
Assessment of ATP production via Complex I in unstressed cells with [A53T]a-Synuclein expression revealed a significant reduction of ATP levels in
TRAP1[D158N] versus TRAP1[WT] expressing cells (t-test, ***p,0.001).
doi:10.1371/journal.pgen.1002488.g005
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content of endogenous, VDAC1 (mitochondrial outer membrane
protein), b-Tubulin (cytosol) and a-Synuclein proteins. Whereas
the input showed abundance of all tested proteins, the cytosolic
fraction displayed expected cytosolic proteins b-Tubulin and a-
Synuclein. In the mitochondria enriched fraction, no contaminat-
ing protein from b-Tubulin could be detected. Importantly,
exogenous [A53T]a-Synuclein protein was found within the
mitochondria enriched fraction (Figure S7B).
Given the strong rescue effect of TRAP1 on toxicity induced by
[A53T]a-Synuclein in various systems (flies, primary rat neurons,
and human cells), this implies at least a genetic interaction of these
proteins. Whether there is a direct interaction of [A53T]a-
Synuclein and TRAP1 awaits further analysis.
Discussion
a-Synuclein plays an important role in PD pathogenesis.
However, the mechanisms that actually lead to a-Synuclein-
induced neurotoxicity remain unresolved. To gain insights into the
disease mechanisms triggered by a-Synuclein, we performed a
genome-wide modifier screen on [A53T]a-Synuclein-induced
toxicity in flies. We used [A53T]a-Synuclein for our screen
because its overexpression in flies results in a robust Parkinsonian
phenotype [21,55–57]. Toxicity induced by a-Synuclein or its
mutant variants is rather low and eye-specific expression of A53T
does not cause rough eye phenotypes (REPs). Such REPs induced
by eye-specific expression of toxic proteins provide an excellent
tool for screens and have successfully been used in the past to
identify genetic interactions applying alterations in eye morphol-
ogy due to photoreceptor degeneration as an endpoint. Given the
low toxicity of [A53T]a-Synuclein, such screening approaches
could not be conducted with regard to a-Synuclein-induced
toxicity in flies. Our genetic screen fulfilled two important
requirements: it utilized (i) an age-dependent model of [A53T]a-
Synuclein toxicity, and (ii) an endpoint that is relevant to PD, this
being the loss of DA. However, apart of being used as a
neurotransmitter, DA in flies is also used for cuticle tanning. Thus,
we cannot exclude the possibility that cuticle-derived DA might
contribute to the overall DA in fly heads. Therefore, the measured
decline is not only connected to DA loss in neurons. Nevertheless,
secondary readouts like locomotion measurements or DA neuron
counts indicate a strong correlation between decreased head DA
content and proper function of DA neurons.
One of the candidates identified in our screen was the
mitochondrial chaperone TRAP1. Consistent with our results, a
genetic screen for alteration of a-Synuclein aggregation, conduct-
ed in C. elegans, identified R151.7, a homologue to Drosophila and
human TRAP1, as a candidate worm gene. Knockdown of R151.7
resulted in premature a-Synuclein aggregation [58]. Although
aggregation was not assayed in our screen, this finding acts as an
external confirmation that TRAP1 genetically interacts with a-
Synuclein in different in vivo systems.
In multiple cell culture systems, TRAP1 has been shown to
provide anti-apoptotic functions [48,52,53] as high levels of
TRAP1 reduce the release of key factors involved in apoptosis,
including Apoptosis Inducing Factor-1 and Cytochrome c, and
additionally prevents Caspase-3 cleavage [39,46,48,59]. The direct
mechanisms by which TRAP1 might inhibit apoptosis were not
examined in this study. However, given that overexpression of
TRAP1 in both rat primary neurons and HEK293 cells was able
to enhance cell survival after rotenone treatment, we hypothesize
that anti-apoptotic mechanisms might in part be responsible for
rescue of [A53T]a-Synuclein toxicity by TRAP1. This is in
agreement with the observation that PD-associated neuronal death
involves apoptotic cell death [60–63]. In addition, the effects of
TRAP1 modulation on ATP synthesis and activities of the ETC
support a mitochondrial function. For more than two decades,
biochemical studies, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP) and transgenic animal models have implicated
mitochondrial dysfunction in the pathogenesis of PD [5,64–71].
Genetic data, including mutations in PINK-1, Parkin, DJ-1, and
HtrA2, have now specifically linked PD to both dysfunction and
morphological change of the mitochondria [72–80]. However, the
relationship of a-Synuclein pathology and mitochondrial dysfunc-
tion has been less clear. Our data are compatible with a
localization of [A53T]a-Synuclein either in mitochondria or in
mitochondrial membranes. Recent findings, though, have indi-
cated that a-Synuclein may be localized to the outer mitochon-
drial membrane in pathological conditions and induce morpho-
logical changes of mitochondria by inhibiting mitochondrial fusion
and enhancing mitochondrial fragmentation [51]. These morpho-
logical changes were rescued by overexpression of wild type
PINK1, Parkin, and DJ-1 [51]. We show here that TRAP1
overexpression is also able to reverse [A53T]a-Synuclein-induced
mitochondrial fragmentation.
Interestingly, TRAP1 has been identified as a substrate of the
serine/threonine kinase PINK1. Phosphorylation of TRAP1 by
PINK1 seems to be required for the protective effects mediated by
PINK1. Combining these data with our findings leads to a
potential pathogenic model, in which [A53T]a-Synuclein induces
mitochondrial stress impairing, most likely, Complex I of the ECT
by an as yet unidentified mechanism. Overexpression of TRAP1
counteracts this effect in flies, primary neurons and human
neuronal as well as non-neuronal cells. TRAP1[D158N] is less
effective in protecting from [A53T]a-Synuclein-induced detri-
mental effects. The finding suggests that a functional ATPase
domain is required for TRAP1 function.
Methods
Fly Stocks
Flies were raised and maintained on standard cornmeal-yeast-
molasses-agar food at 25uC unless otherwise noted. Non-RNAi
stocks were obtained from the Bloomington Drosophila Stock
Centre, UAS-RNAi stocks either from the Vienna Drosophila RNAi
Figure 6. Inhibition of mitochondrial fusion by [A53T]a-Synuclein is rescued by TRAP1. SH-SY5Y cells were co-transfected with the
indicated constructs and mito-DsRed to visualize mitochondria. The mitochondrial morphology of transfected cells was analyzed by fluorescence
microscopy. (A) Confocal images of representative cells displaying either an intact tubular mitochondrial network (control) or a fragmentation of this
network (A53T). Co-expression of TRAP1[WT] prevented [A53T]a-Synuclein-induced mitochondrial fragmentation, whereas the TRAP1[D158N] mutant
did not show rescue activity. Overexpression of either wild type or mutant TRAP1 alone did not influence mitochondrial morphology under steady
state conditions. (B) For quantification, the mitochondrial morphology of at least 300 transfected cells per coverslip was determined in a blinded
manner. Quantifications were based on triplicates of at least three independent experiments. Shown is the percentage of cells with fragmented
mitochondria. (C) Expression levels of [A53T]a-Synuclein and TRAP1 were analyzed by Western blotting. b-Actin served as a loading control.
***p,0.001 (ANOVA).
doi:10.1371/journal.pgen.1002488.g006
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Japan). Bloomington lines used were: Wild type flies (Oregon R;
referred to as + in text), w
1118;; P{Ddc-GAL4.L}4.36 (BL7009; ddc:
dopa decarboxylase, aminergic neuron specific driver, referred to
in text as ddc-GAL4), w
*; P{UAS-lacZ.B}Bg4-2-4b (BL1777; referred
to in text as UAS-LacZ), y
1w
67c23; P{SUPor-P}Trap1
KG06242
(BL14032; referred to in text as TRAP1[KG]), w[*];
P{w[+mC]=longGMR-GAL4} (BL8605; referred to as GMR-
GAL4 in text), w[1118]; P{w[+mC]=UAS-HsapHSPA1L.W}53.1
(BL7455; expresses HSPA1L, the human homolog of HSP70
under GAL4 control; referred to as HSP70 in text), w[1118];
P{w[+mC]=UAS-mitoGFP.AP} (BL8443; expresses GFP with a
mitochondrial import signal; referred to as mito-GFP in text) and
w[*]; P{w[+mC]=UAS-Hsap\MJD.tr-Q78}c211.2 (BL8150; ex-
presses a HA-tagged C-terminal fragment of the human
Machado-Joseph Disease/Spinocerebellar Ataxia 3 protein with
a 78 repeat polyglutamine tract; referred to in text as PolyQ). For
stable eye-specific expression of PolyQ, GMR-GAL4 driver was
recombined with PolyQ transgene (GMR.PolyQ in text). Fly
lines suitable for GFP (yw;; UAS-GFP) or human [A53T]a-
Synuclein (yw;; UAS-[A53T]a-Synuclein [41]) expression (referred
to in text as GFP or A53T, respectively). Stable expression under
control of the ddc driver (w[*];; ddc-GAL4.UAS-GFP; w[*];; ddc-
GAL4.UAS-GFP) were generated by recombination (flies referred
to in text as ddc.GFP or ddc.A53T).
Transgenic flies expressing human TRAP1 (hTRAP1) were
generated by BestGene Inc. In brief, human TRAP1 cDNA was
sub-cloned from pcDNA3.1+ vector into pUASattB using KpnI
and XbaI restriction sites. hTRAP1 expression in these transgenic
flies (w;; UAS-hTRAP1/TM3, Sb; referred to in text as hTRAP1)
was verified by Western blotting.
Genetic Deficiency Screen Breeding
The Bloomington Deficiency Kit was utilized for screening
purposes (http://flystocks.bio.indiana.edu/Browse/df/dfkit_retir-
ed_July2009.htm). In general, a specific deficiency line was
crossbred with ddc.A53T flies. Male offspring (ddc.A53T flies in
combination with the respective deficiency) was selected and aged.
At ages 1 and 4 weeks, a minimum of 9 flies was collected for later
measurement of head DA using HPLC.
Measurement of Fly Head Dopamine (DA) using HPLC
Liquid nitrogen flash frozen fly heads were homogenized
(Precellys 24 homogenizer) in homogenization buffer (0.1 M
perchloric acid/3% trichloric acid solution). 50 ml of supernatant
from each sample were used for HPLC analysis (Dionex Ultimate
3000; running buffer: 57 mM citric acid, 43 mM sodium acetate,
0.1 mM EDTA, 1 mM octane sulfonic acid, 20% methanol).
Samples were separated on a chromatographic column (Dionex
Acclaim C18, 5 mm, 2.16150 mm column, at 25uC), and DA was
electrochemically detected on a graphite electrode (Dionex ED50
Electrochemical detector with following conditions: disposable
carbon electrode at 0.8 V, flow rate 0.2 ml/min). DA (Sigma-
Aldrich) standards of 0.1 mM, 0.25 mM and 0.4 mM were used for
creation of a standard curve. Chromeleon 6.6 software was used
for HPLC data analysis.
Figure 7. Transient siRNA-mediated knockdown of TRAP1
increases [A53T]a-Synuclein-induced mitochondrial fragmen-
tation. SH-SY5Y cells were co-transfected with the siRNAs and plasmids
indicated. Mitochondria were vis u a l i z e db yD s R e dt a r g e t e dt o
mitochondria (mito-DsRed). (A) Confocal images taken of representative
cells displaying either an intact tubular mitochondrial network (control
siRNA) or a fragmentation of the network (control siRNA+A53T).
Transient knockdown of TRAP1 causes mitochondrial fragmentation
itself (TRAP1 siRNA), additional co-expression of [A53T]a-Synuclein
aggravated this phenotype and led to an overall increase in cells
showing a fragmented mitochondrial network (TRAP1 siRNA+A53T). (B)
For quantification, at least 300 transfected cells per coverslip were
analyzed. The mitochondrial morphology was determined in a blinded
manner. Quantifications are based on triplicates of three independent
experiments. (C) Expression levels of [A53T]a-Synuclein and TRAP1 were
analyzed by Western Blotting. b-Actin was used as a loading control.
**p,0.01; ***p,0.001 (ANOVA).
doi:10.1371/journal.pgen.1002488.g007
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Longevity assays were performed as previously described [81].
For oxidative stress assays a minimum of 20 male flies (2–3 days
of age) was kept on filter papers soaked with paraquat (20 mM
paraquat dichloride in 5% sucrose). Survival of flies was scored
on a daily base. Fresh paraquat/sucrose solution was supplied
daily.
Negative Geotaxis Assay
Fly climbing was assessed in accordance with previously
published protocols [21,43,82]. Flies were aged on normal yeast
medium. At ages 1 and 4 weeks, climbing was assessed (20 flies
per genotype). Flies were individually placed in a graduated
cylinder, and allowed to climb for 15 s. Maximum height
attained was recorded, and analysis was repeated 3 times per
time point, with 3 trials at one minute intervals recorded at each
time point.
Immunohistochemistry
Fly brains were dissected in cold PBS, washed in a PBS/0.1%
Triton X (PBT), fixed in 4% PFA (30 min, 4uC), and blocked in
PBT containing 5% normal goat serum (overnight, 4uC). For TH
staining, brains were incubated with primary anti-TH antibody
(1:100; rabbit polyclonal, AB152, Chemicon International/Milli-
pore) for 2 days, 4uC, and subsequently with fluorescent secondary
anti-rabbit antibody (1:200; AlexaFluor-555 or Cy3; Invitrogen/
Jackson Immunological Research) for 3.5 hours. Afterwards,
brains were mounted in Vectashield (Vector Labs). The number
of TH-positive neurons was determined on Z-stacked confocal
sections (1 mm, Leica DM IRE2, Laser) [83]. At least 15 brains
were analyzed per genotype.
Protein Collection and Western Blotting
Fly heads were homogenized in RIPA buffer (50 mM Tris,
pH 8.0, 0.15 M NaCl, 0.1% SDS, 1.0% NP-40, 0.5% Na-
Deoxycholate, 2 mM EDTA, Complete Protease Inhibitors
(Roche Applied Sciences), pH 7.4), centrifuged, and the superna-
tant was collected.
Cell culture protein samples were collected after washing cells in
ice cold PBS, followed by lysis in RIPA buffer for 30 min on ice.
Cell debris was removed by centrifugation, and supernatants were
collected.
For Western blot analysis, protein samples were separated via
SDS-PAGE gel and then transferred onto nitrocellulose mem-
brane. Blocking in skim milk was followed by overnight primary
antibody incubation. The primary antibodies used were as
follows: mouse anti-a-Synuclein (1:1000; Cell Signaling); mouse
anti-Drosophila Syntaxin (1:2000 Developmental Studies Hybrid-
oma Bank (DSHB)), mouse anti-b-Tubulin (1:500, DSHB); mouse
anti-D Tubulin (1:10,000; Sigma-Aldrich); mouse anti-TRAP1
(1:1000; BD Biosystems); mouse anti-phospho-tyrosine (PY99)
(1:200; Santa Cruz Biotechnology); mouse anti-phospho-threo-
nine (H2) (1:200: Santa Cruz Biotechnology); mouse anti-
phospho-serine (16B4) (1:200; Santa Cruz Biotechnology); mouse
anti-Cytochrome c (1:500; Santa Cruz Biotechnology); rabbit
anti-VDAC1 (0.3 mg/ml; Abcam); mouse anti-COX IV (2 mg/
ml; Abcam); rabbit anti-GFP polyclonal (1:1000; Santa Cruz
Biotechnology).
Appropriate secondary anti-mouse or rabbit horseradish
peroxidase-linked antibodies (1:10,000) were obtained from GE
Healthcare. Membranes were incubated with the secondary
antibody for one hour, followed by signal detection using the
Chemiglow substrate (Biozym).
Total RNA Isolation, cDNA Preparation, and Real-Time
PCR
Method for fly head RNA isolation was adapted from the
following link: http://www.ou.edu/journals/dis/DIS84/Tec2%
20Bertucci/Bertucci.htm. 20 fly heads per tube were used for
RNA isolation. RNA samples were treated with DNase following
manufacturer’s instructions (Promega RQ1 RNase-Free DNase
kit). Total RNA from cultured cells was prepared from cells using
Qiagen RNeasy Mini kit (Qiagen). RNA was used for cDNA
production via reverse transcription using the iScript cDNA
Synthesis Kit (BioRad). Real-time PCR measurements were
performed using the SYBR Green (Thermo Fisher Scientific)
reagent following manufacturer’s instructions for preparation of
PCR samples. Gene of interest signal was compared to that of
control gene expression (b-Actin5c for fly samples and 18S for
human samples) using the 2
2DDCt method [84]. No-RT controls
were performed to exclude for genomic DNA sample contamina-
tion. PCR reactions were followed by generation of a dissociation
curve to check for side product generation.
Amplification conditions for fly samples were as follows: 5 min
at 95uC, 40 cycles of: 30 s at 95uC, 30 s at 58uC, 60 s at 72uC,
followed by 10 min at 72uC. Gene of interest was normalized to
control b-Actin5c signal. The primers used are listed in Table S5.
Amplification conditions for cell culture samples were as follows:
5 min at 95uC, 40 cycles of: 30 s at 94uC, 30 s at 60uC, 60 s at
72uC, followed by 10 min at 72uC. Gene of interest was
normalized to control 18S signal. For primers, see Table S5.
Cell Culture
Cloning and in vitro mutagenesis. Full length human a-
Synuclein cDNA (423 bp), carrying the [A53T] mutation (cDNA a
gift from Dr. Felipe Opazo, European Neuroscience Institute,
Go ¨ttingen, Germany) was subcloned into the pcDNA3.1+
expression vector (Invitrogen) using HindIII and EcoRV
restriction sites. Full length human TRAP1 cDNA (2115 bp) was
amplified from human HEK293 cell cDNA samples. BglII and
XhoI restriction sites were introduced using primers listed in Table
S5.
TRAP1 cDNA was then cloned into the pcDNA3.1+ vector
using the BglII, XhoI sites.
In vitro mutagenesis of human TRAP1 in pcDNA3.1+ was
carried out using the QuickChange Site-Directed Mutagenesis kit
(Stratagene) following manufacturer’s instructions. Sites for
mutagenesis were based on conserved sites found in the ATPase
domain (see Figure S6 for sequence homology). PCR cycling
parameters were used as suggested by Stratagene, with a specific
extension time of 8 min and 16 cycles for all reactions. Primers
used for generating the mutants are listed in Table S5.
Lentivirus preparation. Full length human TRAP1 or
[A53T]a-Synuclein cDNA was subcloned into a third generation
lentiviral vector pRRLsin.cPPT.PGK/GFP.WPRE (Tronolab),
excluding the GFP cassette. The GFP-expressing virus served as
a control [85].
Cells, plasmid transfection, and viral infection. Human
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10% fetal calf serum, 100 units/ml
penicillin, and 100 mg/ml streptomycin. Transfection of plasmids
and small interfering RNA (siRNA) into HEK293 cells was
completed using Metafectene (Biontex) following manufacturer’s
instructions. siRNAs used for gene knockdown experiments were
obtained from Qiagen: MAPK1 control siRNA (Qiagen 1027277);
2 different TRAP1 siRNAs (Flexitube siRNA SI03066364 and
siRNA SI00115150); a scrambled siRNA for control (Allstars
Negative Control, 1027280). Final concentration of siRNA used
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(35,000 cells/cm
2) and then transfected 48 hours before
experimentation.
Primary cortical rat neurons were prepared from E18 rat
embryos, following previously published procedures [65]. Neurons
were seeded on poly-ornithin-coated 24-well plates at a density of
125,000 cells/cm
2. Cells were maintained in Neurobasal medium
(Gibco/Invitrogen), supplemented with 5 mg/ml transferrin, 1%
PSN, 0.5 mM L-Glutamine, 2% B27 supplement. Primary
neurons were infected equimolarly with lentiviruses one day after
isolation and then cultured for 6 days before experimental use.
SH-SY5Y cells (DSMZ number ACC 209) were cultured in
DMEM F-12 with glutamine (Lonza) supplemented with 15% (v/
v) fetal calf serum, non-essential amino acids (Invitrogen) and
penicillin/streptomycin. Transfections were performed using
Lipofectamine Plus (Invitrogen) according to the manufacturer’s
instructions. The following plasmids were described earlier:
[A53T]a-Synuclein and mito-DsRed [51]. For downregulation
of TRAP1, SH-SY5Y cells were reversely transfected with the
indicated siRNA and co-transfected with mito-DsRed and empty
vector or [A53T]a-Synuclein using Lipofectamin RNAiMax
(Invitrogen) according to the manufacturers instruction. 24 hours
after transfection, fresh medium was added. Cells were analyzed
48 h after transfection.
Fluorescent staining of mitochondria. SH-SY5Y cells
were plated on 15 mm glass coverslips and co-transfected with
mito-DsRed and the indicated DNA constructs. At 24 h after
transfection, cells were washed twice with ice-cold PBS, fixed with
3.7% paraformaldehyde for 10 minutes at room temperature and
washed twice with PBS before mounting the coverslips.
Transfected cells were identified by co-expression of mito-
DsRed. Cells were categorized in two classes according to their
mitochondrial morphology [75]. Cells displaying an intact network
of tubular mitochondria were classified as tubular. When this
network was disrupted and mitochondria appeared predominantly
spherical or rod-like, they were classified as fragmented. The
mitochondrial morphology of at least 300 cells per coverslip was
determined in a blinded manner using a Leica DMRB
microscope. Quantifications were based on triplicates of at least
three independent experiments. Confocal images of representative
cells were obtained using a Zeiss LSM 510 microscope. a-
Synuclein was detected using a monoclonal anti-rat antibody
described previously [51]. b-Actin was detected using a
monoclonal antibody from Sigma.
Cell Culture Oxidative Stress Testing and Measurement of
Cell Viability
Cells were incubated for 16 hours in the presence of either
hydrogen peroxide (100 mM) or rotenone in DMSO (HEK293:
200 mM, rat cortical: 1 mM rotenone). Rotenone control cells were
treated with equivalent amount of DMSO alone. After overnight
oxidative stress treatment, cells were fixed in 4% PFA for 10 min,
before permeabilization in PBT for 10 min. Cells were incubated
with Hoechst nuclear stain for 30 min before imaging on a
fluorescent microscope (Leica DMI6000B). Using a macro within
the Leica Qwin V3 quantification software, cell number remaining
in each well was assessed by counting total fluorescent nuclei (6
images per well at 106, with minimum 6 wells per genotype in a
24-well culture dish).
ATP Synthesis Assay
Method was adapted from [86]. Cells were trypsinized and
washed three times in cold PBS. Cells were then resuspended in
incubation medium (2610
5 cells/ml, 25 mM Tris, 125 mM KCl,
2m MK +EDTA, 10 mM KH2PO4, pH 7.4) and permeabilized
with digitonin (40 mg/ml). To measure ATP produced via
complexes I, III, IV, 2610
4 cells (minimum of 8 replicates per
experiment) were resuspended in a complex incubation medium
supplemented with 1 mg/ml BSA, 2 mM ADP, 10 mM gluta-
mate, 2 mM malate. After incubation for 20 min at 37uC, the
reaction was stopped by addition of 6% perchloric acid, and
samples were neutralized with 3 M K2CO3. ATP in each sample
was measured in a plate reader using the CellTiter-Glo
Luminescent reagent (Promega) following manufacturer-provided
instructions. Total ATP levels were obtained using an ATP
standard curve (ATP from Sigma), with final calculation
expressing ATP as pmoles ATP per minute per 1 million cells,
and plotted as percentage of control values.
Measurement of Steady State Cellular ATP
2610
4 HEK293 cells/well were seeded (12 replicates per
experiment) in an opaque white 96-well plate. Total ATP levels
were measured as stated above.
Assessment of Mitochondrial Membrane Potential
Following manufacturer-provided instructions, cells (6 replicates
per experiment) in a 96-well plate (black sided, clear bottom) were
incubated with the mitochondrial probe JC-1 (3 mg/ml; Invitro-
gen) in full medium for 30 min at 37uC. After washing in PBS, JC-
1 mitochondrial aggregates were measured in a plate reader
(excitation: 530 nm, emission: 590 nm). As a control, JC-1
fluorescence was measured in the presence of the mitochondrial
membrane potential inhibitor CCCP (Carbonyl cyanide m-
chlorophenylhydrazone, 50 mM). Protein content per well was
quantified using the Bradford assay. Fluorescence in relation to
total protein was displayed as percentage of control values.
Immunocytochemistry
Cells were plated on PLL-coated glass slips. 48 hours after
transfection, cells were fixed in 4% PFA for 10 min, permeabilized
in PBT for 10 min, followed by blocking in 1% BSA and overnight
incubation with the primary antibody at 4uC. Antibodies used:
monoclonal rat anti-a-Synuclein (1:500, Alexis Biochemicals/
Enzo Life Sciences); monoclonal mouse anti-NeuN (1:500,
Chemicon); monoclonal mouse anti-TRAP1 (1:300, Alexis
Biochemicals). For visualization of mitochondria cells pretreated
for 4 hours with 1 mM rotenone, the cells were incubated with
Mitotracker Orange CMTMRos (300 nM, following manufactur-
er’s instructions, Invitrogen) for 30 min at 37uC prior to fixation.
Cells were incubated with respective secondary antibodies for one
hour (all secondary antibodies 1:1000, anti-mouse or rat Alexa-
Fluor-488, 543, 633, Invitrogen), and mounted using Mowiol
(Calbiochem), with or without the anti-bleaching agent DABCO
or nuclear stain Hoechst (Sigma-Aldrich).
Mitochondrial Isolation
Mitochondria were isolated from HEK293 cells transfected with
[A53T]a-Synuclein using the following protocol: Cells were
suspended in MB buffer (70 mM sucrose, 10 mM HEPES,
1 mM EDTA, 210 nM Mannitol (pH 7.5) and protease inhibi-
tors), homogenized with an injection needle (27G L0 19 mm, 5–6
strokes) and centrifuged at 7506g for 7 min. After centrifugation
the pellet was resuspended in MB buffer, homogenized using the
same injection needle and centrifuged. This procedure was
repeated four times. The resulting supernatants were pooled and
centrifuged at 100006g for 30 min. This mitochondria-containing
pellet was resuspended in MB buffer and further centrifugated at
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pellet was examined by Western blotting using specific antibodies
directed against b-Tubulin, VDAC and a-Synuclein.
Statistics
Data was analyzed using GraphPad Prism 4.0 (GraphPad
Software Inc.), using 1-way ANOVA followed by Newman-Keuls
post testing. Use of a 2-way ANOVA was noted in the text.
Survival data were analyzed with the Kaplan-Meier analysis
method and the Log Rank Test for curve statistical comparison
analysis. Statistical significance referred to as: *p,0.05; **p,0.01;
***p,0.001. All data is presented as mean 6 SEM.
Supporting Information
Figure S1 Validation, specificity and sensitivity of HPLC to
measure fly head DA. (A) Number of fly heads for single
measurement varied from 3–30 and absolute DA amounts
measured by HPLC were analyzed via linear regression;
r
2=0.997 (n=3). (B) Fly heads collected at indicated time of
day were analyzed for DA using HPLC. Significant difference
(ANOVA followed by Newman-Keuls Multiple Comparison Test)
between time points noted: *p,0.05 vs. 10:30 and 16:30 (n=3).
(C) Wild type flies (one day post eclosion) were daily treated with
tyrosine hydroxylase inhibitor a-methyltyrosine (a-MT). Fly heads
were collected at 2-day intervals for measurement of DA using
HPLC: Significant differences (t-test): *p,0.05 for Control
(untreated) vs. 5 mM a-MT (n=3).
(JPG)
Figure S2 Determination of TRAP1 transcript abundance. Flies
heterozygous for P-element insertion TRAP1[KG] displayed a
significant reduction in trap1 transcript levels normalized to actin5C
independent of [A53T]a-Synuclein expression (t-test, compared to
respective control; **p,0.01; ***p,0.001).
(JPG)
Figure S3 Immunocytochemistry of [A53T]a-Synuclein-express-
ing HEK293 cells with overexpression or downregulation of
TRAP1. (A) HEK293 cells transfected with [A53T]a-Synuclein
were stained for TRAP1 (red), a-Synuclein (green) and DNA (blue).
Merged picture is shown (right column). Upper panel: [A53T]a-
Synuclein expressing cells co-transfected with empty vector. Middle
panel: [A53T]a-Synuclein expressing cells with siTRAP1. Lower
panel: Cells with [A53T]a-Synuclein and TRAP1 overexpression
(scale bar=24 mm). (B) Transfection with siTRAP1 reduced
endogenous TRAP1 transcripts (in relation to b-Actin). (C) Both
siTRAP1-1 and siTRAP1-2 resulted in significant knockdown of
TRAP1 expression (ANOVA followed by Newman-Keuls Multiple
Comparison Test; n=3; ***p,0.001; ns=not significant).
(JPG)
Figure S4 Assessment of mitochondrial proteins. Changes in
mitochondrial function by (A) alterations of TRAP1 levels or (B)
expression of mutant TRAP1[D158N] are not caused by a
decrease in overall mitochondrial load. Western blot analysis of
HEK293 transfected with indicated constructs were assayed for
abundance of the mitochondrial proteins VDAC1 and COX4. b-
Actin served as loading control.
(JPG)
Figure S5 Stable silencing of TRAP1 causes a reduction in
membrane potential of [A53T]a-Synuclein-expressing cells. We
stably silenced TRAP1 in HEK293 cells using Lentiviruses-
expressing short hairpin RNA (shRNA). (A) Silencing of TRAP1
was verified by Western blot. In contrast to HEK cells with stable
expression of a scrambled shRNA construct, TRAP1-silenced cells
displayed a strong reductionof TRAP1 protein load. Quantification
of Western blots (n$3) normalized with either VDAC or Tubulin
revealed a strong reduction of TRAP1 in cells expressing shTRAP1
(95.43+/21.25%). The presence of similar amounts of VDAC in
relation to Tubulin between scrambled shRNA-expressing and
TRAP1-silenced cells indicates that mitochondrial load is not
effected by shTRAP1. (B) Membrane potential was measured using
the dye TMRM. Cells with stable expression of either of scrambled
shRNA or TRAP1 shRNA were co-transfected with pEPFP-N1, in
combination with pCDNA3.1 or pCDNA3.1-[A53T]a-Synuclein.
2 days after transfection cells were treated with 200 nM TMRM for
30 minutes at 37uC. Fluorescence was measured at 573 nm
(TMRM) and 509 nm (EGFP) and plotted as relative intensity
(TMRM/GFP). Cells expressing scrambled shRNA displayed non-
significant (ns) changes in membrane potential with or without
[A53T]a-Synuclein-expression. In contrast, expression of [A53T]a-
Synuclein caused a significant reduction in membrane potential of
TRAP1-silenced cells (***p,0.001). Statistic: 2-way ANOVA
followed by Bonferroni post-hoc tests.
(JPG)
Figure S6 Protein sequence data for TRAP1 used for mutant
generation. (A) Protein sequence alignment showing conserved
aspartic acid in HSP90 ATPase domains. The indicated conserved
amino acid is reported to be critical for ATPase function in yeast
Hsp82. Moreover, this aspartic acid is conserved in ATPase
domains of human TRAP1 (position 158). (B) Multiple sequence
comparison of TRAP1 proteins from different species showed a
high degree of conservation of this aspartic acid in the ATPase
domain. Alignments were performed using ClustalW2 (http://
www.ebi.ac.uk/Tools/msa/clustalw2/).
(JPG)
Figure S7 Localization of TRAP1 and [A53T]a-Synuclein to
the mitochondria. (A) Mitochondrial localization of TRAP1.
Confocal section of HEK293 cells stained with the mitochondrial
marker ‘‘Mitotracker Orange’’ (red), hTRAP1-specific antibody
(green) and Hoechst nuclear stain (blue). A high degree of co-
localization of red and green fluorescent signals is apparent in
overlay. Scale bar indicates 27 mm. (B) Cell fractionation assay
indicates localization of [A53T]a-Synuclein in mitochondria-
enriched fraction. Samples derived after fractionation were used
for Western blot analysis. Blots were probed with specific
antibodies detecting a-Synuclein, VDAC1 and ß-Tubulin. Frac-
tions analyzed (input, cytoplasmic and mitochondrial-enriched
fraction) are indicated.
(JPG)
Figure S8 Detailed statistical analysis of the data shown in
Figure 4. Summary of statistical analysis of bar graphs in
Figure 4A–4C (ANOVA followed by Newman-Keuls Multiple
Comparison Test). *p,0.05; **p,0.01; ***p,0.001; ns=not
significant.
(JPG)
Table S1 List of deficiencies identified to cause haploinsuffi-
ciency with ddc.A53T.
(PDF)
Table S2 List of deficiencies identified to cause semi-lethality.
(PDF)
Table S3 Detailed summary of analyzed genes located within
deficiencies causing a haploinsufficiency in combination with
ddc.A53T.
(PDF)
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Text S1 Brief summary of screen results.
(DOC)
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